There are currently 1084 clinical trials in Rochester, Minnesota looking for participants to engage in research studies. Trials are conducted at various facilities, including Mayo Clinic, Mayo Clinic in Rochester, Mayo Clinic - Rochester and Mayo Clinic Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
NCT05366881
Recruiting
This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types. The cancers included in this study are brain, breast, bladder, cervical, colorectal, endometrial, esophageal, gastric, head and neck, hepatobiliary, leukemia, lung, lymphoma, multiple myeloma, ovarian, pancreatic, prostate, renal, sarcoma, and thyroid. These cancers were selected based on their prevalence and mort... Read More
Gender:
ALL
Ages:
40 years and above
Trial Updated:
02/15/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Brain Cancer, Breast Cancer, Bladder Cancer, Cervical Cancer, Colorectal Cancer, Endometrial Cancer, Esophageal Cancer, Stomach Cancer, Head and Neck Cancer, Hepatobiliary Cancer, Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Renal Cancer, Sarcoma, Thyroid Cancer
Register for Updates
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough (CALM-2)
NCT05600777
Recruiting
This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
02/14/2024
Locations: Mayo Clinic - Rochester, Rochester, Minnesota
Conditions: Refractory Chronic Cough
Register for Updates
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
NCT04849728
Recruiting
This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/24/2024
Locations: Mayo Clinic - Rochester, Rochester, Minnesota
Conditions: NASH - Nonalcoholic Steatohepatitis
Register for Updates
Ablation With Confirmation of Colorectal Liver Metastases (ACCLAIM)
NCT05265169
Recruiting
To demonstrate that microwave ablation (MWA) of up to 3 hepatic metastases, each with a maximum diameter of ≤ 2.5 cm will result in a 2-year local progression free survival of at least 90%. This is a standard of care (SOC) study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/16/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Colorectal Liver Metastases
Register for Updates
Open Nipple Sparing Mastectomy (NSM)
NCT04447339
Recruiting
This is retrospective, multicenter chart review is to evaluate the complication rates of prophylactic open NSM procedures through 42 days postoperatively
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/17/2023
Locations: Mayo Clinic Hosp - Methodist Campus - MN, Rochester, Minnesota
Conditions: Nipple Sparing Mastectomy
Register for Updates
TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery
NCT04197687
Recruiting
This phase II trial studies how well TPIV100 and sargramostim work in treating patients with HER2 positive, stage II-III breast cancer that has residual disease after chemotherapy prior to surgery. It also studies why some HER2 positive breast cancer patients respond better to chemotherapy in combination with trastuzumab and pertuzumab. TPIV100 is a type of vaccine made from HER2 peptide that may help the body build an effective immune response to kill tumor cells that express HER2. Sargramostim... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/15/2023
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Breast Adenocarcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
Register for Updates
Complex Abdominal Aortic Aneurysm Repair With Fenestrated Stent Grafts
NCT01937949
Recruiting
The purpose of this study is to evaluate clinical outcomes and quality of life measures in treated by endovascular aortic repair of juxtarenal, suprarenal, and type IV thoracoabdominal aortic aneurysms using custom-made Cook Zenith® Fenestrated AAA Endovascular Graft.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/02/2023
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Juxtarenal Aortic Aneurysms, Suprarenal Aortic Aneurysms, Type IV Thoracoabdominal Aortic Aneurysms
Register for Updates
Complex Abdominal, TAAA, Aortic Arch Aneurysm or Dissections With Fenestrated/Branched Stent Graft
NCT02089607
Recruiting
The purpose of this study is to gather safety and effectiveness of the Zenith t-Branch and customized physician-specified stent-graft with a combination of fenestrations and/or branches to repair aortic aneurysm.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/02/2023
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Thoracoabdominal Aortic Aneurysm, Aortic Arch Aneurysm, Complex Abdominal Aortic Aneurysm, Aortic Arch Dissection
Register for Updates
Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C Melanoma Patients
NCT03567889
Recruiting
The trial aims to evaluate the efficacy of Daromun neoadjuvant treatment followed by surgery and adjuvant therapy to improve in a statistically significant manner the recurrence-free survival (RFS) of Stage IIIB/C melanoma patients with respect to the standard of care (surgery and adjuvant therapy).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/29/2023
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Melanoma Stage IIIB/C
Register for Updates
Transcatheter Mitral Valve Repair for Inotrope Dependent Cardiogenic Shock
NCT05298124
Recruiting
Mitral regurgitation may be seen in the setting of cardiogenic shock. Transcatheter edge-to-edge repair (TEER) has been shown to improve outcomes in patients with chronic heart failure. Observational studies suggest improvements in clinical outcomes in patients with mitral regurgitation in the setting of cardiogenic shock; however, there remains a lack of randomized clinical data to support the use of TEER in cardiogenic shock. This study will be a multicenter, open-label, randomized-controlled... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/07/2023
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Cardiogenic Shock, Mitral Regurgitation
Register for Updates
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors
NCT03129139
Recruiting
A Phase I, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of Minnelide™Capsules given daily for 21 days followed by 7 days off schedule in patients with Advanced Solid Tumors
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/17/2023
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Advanced Cancer, Gastric Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer Metastatic, Colo-rectal Cancer, Solid Tumor, Solid Carcinoma, Solid Carcinoma of Stomach, Cancer of Stomach
Register for Updates
EASE: The Materna Prep Pivotal Study
NCT03973281
Recruiting
This study is designed to evaluate the safety and effectiveness of the Materna Prep Device in reducing pelvic muscle injuries during vaginal delivery. Subjects are randomized to Materna Prep Device or Standard of Care without use of the Materna Prep Device Intervention with the Materna Prep Device is expected to be a one-time use of approximately 30-90 minutes during the 1st stage of labor. Subject participation in the study is targeted to be 12 months from the time of the use of the device d... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/17/2023
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Vaginal Delivery, Pelvic Organ Prolapse
Register for Updates